Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma

por Zhang, Yang, Qiu, Miao-Zhen, Wang, Ju-Feng, Zhang, Yan-Qiao, Shen, Ao, Yuan, Xiang-Lin, Zhang, Tao, Wei, Xiao-Li, Zhao, Hong-Yun, Wang, De-Shen, Zhao, Qi, Xiong, Gao-Zhun, Ji, Yan-Ping, Liang, Xue-Jun, Xia, Gang, Xu, Rui-Hua
Publicado 2022